The global Oral Obesity Therapies market was valued at US$ 4321 million in 2025 and is anticipated to reach US$ 7310 million by 2032, at a CAGR of 7.7% from 2026 to 2032.

Oral Obesity Therapies Market

Oral Obesity Therapies refer to systemic pharmacological treatments administered orally to manage body weight and improve metabolic health. These therapies include small-molecule drugs, incretin modulators, appetite suppressants, and metabolic regulators designed to influence central appetite signaling, delay gastric emptying, enhance fat oxidation, or reduce nutrient absorption. Compared with injectable GLP-1 therapies, oral formulations offer improved patient compliance, convenience, and broader acceptance. As obesity is increasingly recognized as a chronic disease requiring long-term management, oral obesity therapies are evolving from short-term weight-loss solutions into comprehensive metabolic intervention strategies.The average gross profit margin of this product is 60%.

The rising global prevalence of obesity and related chronic diseases is the primary growth driver for oral obesity therapies. Increasing public health awareness and expanded reimbursement coverage are integrating long-term weight management into formal treatment pathways. Breakthroughs in GLP-1 receptor agonists, oral small-molecule alternatives, and multi-target combination therapies have significantly improved efficacy and safety profiles. Strong capital market interest in metabolic disease innovation is accelerating drug development. The expansion of digital health platforms and telemedicine further enhances patient access to oral treatment options.

Key challenges include stringent regulatory scrutiny on safety, the need for long-term efficacy data, and management of potential adverse effects. Some therapies may carry cardiovascular or psychiatric risks, increasing clinical and post-marketing surveillance costs. Patent competition and generic entry may pressure margins. High patient expectations for weight reduction outcomes can impact market reputation if results fall short. Pricing structures and reimbursement policies also influence market penetration rates.

Demand trends reflect a shift toward chronic disease management and younger patient demographics. The obese population increasingly includes working-age adults seeking convenient and safe long-term oral solutions. Female consumers and individuals at high risk of metabolic syndrome represent major growth segments. Physician-driven prescriptions are strengthening, transforming weight loss from aesthetic motivation to medical management. Consumers prioritize clinical validation and scientific endorsement. Online medical consultation and pharmaceutical delivery models are further expanding market reach.

Upstream components include active pharmaceutical ingredients, small-molecule intermediates, incretin analog precursors, excipients, and controlled-release carrier systems. Advanced chemical synthesis and biotechnological platforms form the technical foundation. Core ingredients often rely on specialized API manufacturers with high technical barriers. Formulation development emphasizes stability and bioavailability enhancement, with controlled-release and enteric coating technologies playing critical roles. Sustainable manufacturing processes and quality traceability systems are emerging as competitive differentiators within the supply chain.

This report delivers a comprehensive overview of the global Oral Obesity Therapies market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oral Obesity Therapies. The Oral Obesity Therapies market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Oral Obesity Therapies market comprehensively. Regional market sizes by Type, by Application, by Drug Type, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Oral Obesity Therapies manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Oral Obesity Therapies Market Report

Report Metric	Details
Report Name	Oral Obesity Therapies Market
Accounted market size in 2025	US$ 4321 million
Forecasted market size in 2032	US$ 7310 million
CAGR	7.7%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Lipase Inhibitors Sympathomimetic Appetite Suppressants Oral GLP-1 Agonists Other
Segment by Drug Type	Small Molecules Peptide Oral Combination Drugs Other
Segment by Patient Indication	BMI ≥30 Primary Obesity Overweight + Metabolic Comorbidities Short-term Weight Reduction Weight Maintenance
Segment by Application	Hospitals Retail Pharmacies Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Currax Pharmaceuticals, LLC, Vivus, Inc., Roche Holding AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Novo Nordisk A/S, Pfizer Inc., Arena Pharmaceuticals, Inc., Rhythm Pharmaceuticals, Inc., Gelesis
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Drug Type, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Oral Obesity Therapies companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Oral Obesity Therapies Market growing?

Ans: The Oral Obesity Therapies Market witnessing a CAGR of 7.7% during the forecast period 2026-2032.

What is the Oral Obesity Therapies Market size in 2032?

Ans: The Oral Obesity Therapies Market size in 2032 will be US$ 7310 million.

Who are the main players in the Oral Obesity Therapies Market report?

Ans: The main players in the Oral Obesity Therapies Market are Currax Pharmaceuticals, LLC, Vivus, Inc., Roche Holding AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Novo Nordisk A/S, Pfizer Inc., Arena Pharmaceuticals, Inc., Rhythm Pharmaceuticals, Inc., Gelesis

What are the Application segmentation covered in the Oral Obesity Therapies Market report?

Ans: The Applications covered in the Oral Obesity Therapies Market report are Hospitals, Retail Pharmacies, Other

What are the Type segmentation covered in the Oral Obesity Therapies Market report?

Ans: The Types covered in the Oral Obesity Therapies Market report are Small Molecules, Peptide Oral, Combination Drugs, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Oral Obesity Therapies Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Lipase Inhibitors

1.2.3 Sympathomimetic Appetite Suppressants

1.2.4 Oral GLP-1 Agonists

1.2.5 Other

1.3 Market by Drug Type

1.3.1 Global Oral Obesity Therapies Market Size Growth Rate by Drug Type: 2021 vs 2025 vs 2032

1.3.2 Small Molecules

1.3.3 Peptide Oral

1.3.4 Combination Drugs

1.3.5 Other

1.4 Market by Patient Indication

1.4.1 Global Oral Obesity Therapies Market Size Growth Rate by Patient Indication: 2021 vs 2025 vs 2032

1.4.2 BMI ≥30 Primary Obesity

1.4.3 Overweight + Metabolic Comorbidities

1.4.4 Short-term Weight Reduction

1.4.5 Weight Maintenance

1.5 Market by Application

1.5.1 Global Oral Obesity Therapies Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Hospitals

1.5.3 Retail Pharmacies

1.5.4 Other

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Oral Obesity Therapies Market Perspective (2021–2032)

2.2 Global Oral Obesity Therapies Growth Trends by Region

2.2.1 Global Oral Obesity Therapies Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Oral Obesity Therapies Historic Market Size by Region (2021–2026)

2.2.3 Oral Obesity Therapies Forecasted Market Size by Region (2027–2032)

2.3 Oral Obesity Therapies Market Dynamics

2.3.1 Oral Obesity Therapies Industry Trends

2.3.2 Oral Obesity Therapies Market Drivers

2.3.3 Oral Obesity Therapies Market Challenges

2.3.4 Oral Obesity Therapies Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Oral Obesity Therapies Players by Revenue

3.1.1 Global Top Oral Obesity Therapies Players by Revenue (2021–2026)

3.1.2 Global Oral Obesity Therapies Revenue Market Share by Players (2021–2026)

3.2 Global Top Oral Obesity Therapies Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Oral Obesity Therapies Revenue

3.4 Global Oral Obesity Therapies Market Concentration Ratio

3.4.1 Global Oral Obesity Therapies Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Oral Obesity Therapies Revenue in 2025

3.5 Global Key Players of Oral Obesity Therapies Head Offices and Areas Served

3.6 Global Key Players of Oral Obesity Therapies, Products and Applications

3.7 Global Key Players of Oral Obesity Therapies, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Oral Obesity Therapies Breakdown Data by Type

4.1 Global Oral Obesity Therapies Historic Market Size by Type (2021–2026)

4.2 Global Oral Obesity Therapies Forecasted Market Size by Type (2027–2032)

5 Oral Obesity Therapies Breakdown Data by Application

5.1 Global Oral Obesity Therapies Historic Market Size by Application (2021–2026)

5.2 Global Oral Obesity Therapies Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Oral Obesity Therapies Market Size (2021–2032)

6.2 North America Oral Obesity Therapies Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Oral Obesity Therapies Market Size by Country (2021–2026)

6.4 North America Oral Obesity Therapies Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Oral Obesity Therapies Market Size (2021–2032)

7.2 Europe Oral Obesity Therapies Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Oral Obesity Therapies Market Size by Country (2021–2026)

7.4 Europe Oral Obesity Therapies Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Oral Obesity Therapies Market Size (2021–2032)

8.2 Asia-Pacific Oral Obesity Therapies Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Oral Obesity Therapies Market Size by Region (2021–2026)

8.4 Asia-Pacific Oral Obesity Therapies Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Oral Obesity Therapies Market Size (2021–2032)

9.2 Latin America Oral Obesity Therapies Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Oral Obesity Therapies Market Size by Country (2021–2026)

9.4 Latin America Oral Obesity Therapies Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Oral Obesity Therapies Market Size (2021–2032)

10.2 Middle East & Africa Oral Obesity Therapies Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Oral Obesity Therapies Market Size by Country (2021–2026)

10.4 Middle East & Africa Oral Obesity Therapies Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Currax Pharmaceuticals, LLC

11.1.1 Currax Pharmaceuticals, LLC Company Details

11.1.2 Currax Pharmaceuticals, LLC Business Overview

11.1.3 Currax Pharmaceuticals, LLC Oral Obesity Therapies Introduction

11.1.4 Currax Pharmaceuticals, LLC Revenue in Oral Obesity Therapies Business (2021–2026)

11.1.5 Currax Pharmaceuticals, LLC Recent Development

11.2 Vivus, Inc.

11.2.1 Vivus, Inc. Company Details

11.2.2 Vivus, Inc. Business Overview

11.2.3 Vivus, Inc. Oral Obesity Therapies Introduction

11.2.4 Vivus, Inc. Revenue in Oral Obesity Therapies Business (2021–2026)

11.2.5 Vivus, Inc. Recent Development

11.3 Roche Holding AG

11.3.1 Roche Holding AG Company Details

11.3.2 Roche Holding AG Business Overview

11.3.3 Roche Holding AG Oral Obesity Therapies Introduction

11.3.4 Roche Holding AG Revenue in Oral Obesity Therapies Business (2021–2026)

11.3.5 Roche Holding AG Recent Development

11.4 Teva Pharmaceutical Industries Ltd.

11.4.1 Teva Pharmaceutical Industries Ltd. Company Details

11.4.2 Teva Pharmaceutical Industries Ltd. Business Overview

11.4.3 Teva Pharmaceutical Industries Ltd. Oral Obesity Therapies Introduction

11.4.4 Teva Pharmaceutical Industries Ltd. Revenue in Oral Obesity Therapies Business (2021–2026)

11.4.5 Teva Pharmaceutical Industries Ltd. Recent Development

11.5 Sun Pharmaceutical Industries Ltd.

11.5.1 Sun Pharmaceutical Industries Ltd. Company Details

11.5.2 Sun Pharmaceutical Industries Ltd. Business Overview

11.5.3 Sun Pharmaceutical Industries Ltd. Oral Obesity Therapies Introduction

11.5.4 Sun Pharmaceutical Industries Ltd. Revenue in Oral Obesity Therapies Business (2021–2026)

11.5.5 Sun Pharmaceutical Industries Ltd. Recent Development

11.6 Novo Nordisk A/S

11.6.1 Novo Nordisk A/S Company Details

11.6.2 Novo Nordisk A/S Business Overview

11.6.3 Novo Nordisk A/S Oral Obesity Therapies Introduction

11.6.4 Novo Nordisk A/S Revenue in Oral Obesity Therapies Business (2021–2026)

11.6.5 Novo Nordisk A/S Recent Development

11.7 Pfizer Inc.

11.7.1 Pfizer Inc. Company Details

11.7.2 Pfizer Inc. Business Overview

11.7.3 Pfizer Inc. Oral Obesity Therapies Introduction

11.7.4 Pfizer Inc. Revenue in Oral Obesity Therapies Business (2021–2026)

11.7.5 Pfizer Inc. Recent Development

11.8 Arena Pharmaceuticals, Inc.

11.8.1 Arena Pharmaceuticals, Inc. Company Details

11.8.2 Arena Pharmaceuticals, Inc. Business Overview

11.8.3 Arena Pharmaceuticals, Inc. Oral Obesity Therapies Introduction

11.8.4 Arena Pharmaceuticals, Inc. Revenue in Oral Obesity Therapies Business (2021–2026)

11.8.5 Arena Pharmaceuticals, Inc. Recent Development

11.9 Rhythm Pharmaceuticals, Inc.

11.9.1 Rhythm Pharmaceuticals, Inc. Company Details

11.9.2 Rhythm Pharmaceuticals, Inc. Business Overview

11.9.3 Rhythm Pharmaceuticals, Inc. Oral Obesity Therapies Introduction

11.9.4 Rhythm Pharmaceuticals, Inc. Revenue in Oral Obesity Therapies Business (2021–2026)

11.9.5 Rhythm Pharmaceuticals, Inc. Recent Development

11.10 Gelesis

11.10.1 Gelesis Company Details

11.10.2 Gelesis Business Overview

11.10.3 Gelesis Oral Obesity Therapies Introduction

11.10.4 Gelesis Revenue in Oral Obesity Therapies Business (2021–2026)

11.10.5 Gelesis Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Currax Pharmaceuticals LLC

VIVUS

Roche Holding AG

Teva Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd.

Novo Nordisk A S

Pfizer Inc

Arena Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc.

Gelesis

List of Tables

Table 1. Global Oral Obesity Therapies Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Lipase Inhibitors

Table 3. Key Players of Sympathomimetic Appetite Suppressants

Table 4. Key Players of Oral GLP-1 Agonists

Table 5. Key Players of Other

Table 6. Global Oral Obesity Therapies Market Size Growth Rate by Drug Type (US$ Million): 2021 vs 2025 vs 2032

Table 7. Key Players of Small Molecules

Table 8. Key Players of Peptide Oral

Table 9. Key Players of Combination Drugs

Table 10. Key Players of Other

Table 11. Global Oral Obesity Therapies Market Size Growth Rate by Patient Indication (US$ Million): 2021 vs 2025 vs 2032

Table 12. Key Players of BMI ≥30 Primary Obesity

Table 13. Key Players of Overweight + Metabolic Comorbidities

Table 14. Key Players of Short-term Weight Reduction

Table 15. Key Players of Weight Maintenance

Table 16. Global Oral Obesity Therapies Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global Oral Obesity Therapies Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 18. Global Oral Obesity Therapies Market Size by Region (US$ Million), 2021–2026

Table 19. Global Oral Obesity Therapies Market Share by Region (2021–2026)

Table 20. Global Oral Obesity Therapies Forecasted Market Size by Region (US$ Million), 2027–2032

Table 21. Global Oral Obesity Therapies Market Share by Region (2027–2032)

Table 22. Oral Obesity Therapies Market Trends

Table 23. Oral Obesity Therapies Market Drivers

Table 24. Oral Obesity Therapies Market Challenges

Table 25. Oral Obesity Therapies Market Restraints

Table 26. Global Oral Obesity Therapies Revenue by Players (US$ Million), 2021–2026

Table 27. Global Oral Obesity Therapies Market Share by Players (2021–2026)

Table 28. Global Top Oral Obesity Therapies Players by Tier (Tier 1, Tier 2, and Tier 3), based on Oral Obesity Therapies Revenue, 2025

Table 29. Ranking of Global Top Oral Obesity Therapies Companies by Revenue (US$ Million) in 2025

Table 30. Global 5 Largest Players Market Share by Oral Obesity Therapies Revenue (CR5 and HHI), 2021–2026

Table 31. Global Key Players of Oral Obesity Therapies, Headquarters and Area Served

Table 32. Global Key Players of Oral Obesity Therapies, Products and Applications

Table 33. Global Key Players of Oral Obesity Therapies, Date of General Availability (GA)

Table 34. Mergers and Acquisitions, Expansion Plans

Table 35. Global Oral Obesity Therapies Market Size by Type (US$ Million), 2021–2026

Table 36. Global Oral Obesity Therapies Revenue Market Share by Type (2021–2026)

Table 37. Global Oral Obesity Therapies Forecasted Market Size by Type (US$ Million), 2027–2032

Table 38. Global Oral Obesity Therapies Revenue Market Share by Type (2027–2032)

Table 39. Global Oral Obesity Therapies Market Size by Application (US$ Million), 2021–2026

Table 40. Global Oral Obesity Therapies Revenue Market Share by Application (2021–2026)

Table 41. Global Oral Obesity Therapies Forecasted Market Size by Application (US$ Million), 2027–2032

Table 42. Global Oral Obesity Therapies Revenue Market Share by Application (2027–2032)

Table 43. North America Oral Obesity Therapies Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 44. North America Oral Obesity Therapies Market Size by Country (US$ Million), 2021–2026

Table 45. North America Oral Obesity Therapies Market Size by Country (US$ Million), 2027–2032

Table 46. Europe Oral Obesity Therapies Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 47. Europe Oral Obesity Therapies Market Size by Country (US$ Million), 2021–2026

Table 48. Europe Oral Obesity Therapies Market Size by Country (US$ Million), 2027–2032

Table 49. Asia-Pacific Oral Obesity Therapies Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 50. Asia-Pacific Oral Obesity Therapies Market Size by Region (US$ Million), 2021–2026

Table 51. Asia-Pacific Oral Obesity Therapies Market Size by Region (US$ Million), 2027–2032

Table 52. Latin America Oral Obesity Therapies Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 53. Latin America Oral Obesity Therapies Market Size by Country (US$ Million), 2021–2026

Table 54. Latin America Oral Obesity Therapies Market Size by Country (US$ Million), 2027–2032

Table 55. Middle East & Africa Oral Obesity Therapies Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 56. Middle East & Africa Oral Obesity Therapies Market Size by Country (US$ Million), 2021–2026

Table 57. Middle East & Africa Oral Obesity Therapies Market Size by Country (US$ Million), 2027–2032

Table 58. Currax Pharmaceuticals, LLC Company Details

Table 59. Currax Pharmaceuticals, LLC Business Overview

Table 60. Currax Pharmaceuticals, LLC Oral Obesity Therapies Product

Table 61. Currax Pharmaceuticals, LLC Revenue in Oral Obesity Therapies Business (US$ Million), 2021–2026

Table 62. Currax Pharmaceuticals, LLC Recent Development

Table 63. Vivus, Inc. Company Details

Table 64. Vivus, Inc. Business Overview

Table 65. Vivus, Inc. Oral Obesity Therapies Product

Table 66. Vivus, Inc. Revenue in Oral Obesity Therapies Business (US$ Million), 2021–2026

Table 67. Vivus, Inc. Recent Development

Table 68. Roche Holding AG Company Details

Table 69. Roche Holding AG Business Overview

Table 70. Roche Holding AG Oral Obesity Therapies Product

Table 71. Roche Holding AG Revenue in Oral Obesity Therapies Business (US$ Million), 2021–2026

Table 72. Roche Holding AG Recent Development

Table 73. Teva Pharmaceutical Industries Ltd. Company Details

Table 74. Teva Pharmaceutical Industries Ltd. Business Overview

Table 75. Teva Pharmaceutical Industries Ltd. Oral Obesity Therapies Product

Table 76. Teva Pharmaceutical Industries Ltd. Revenue in Oral Obesity Therapies Business (US$ Million), 2021–2026

Table 77. Teva Pharmaceutical Industries Ltd. Recent Development

Table 78. Sun Pharmaceutical Industries Ltd. Company Details

Table 79. Sun Pharmaceutical Industries Ltd. Business Overview

Table 80. Sun Pharmaceutical Industries Ltd. Oral Obesity Therapies Product

Table 81. Sun Pharmaceutical Industries Ltd. Revenue in Oral Obesity Therapies Business (US$ Million), 2021–2026

Table 82. Sun Pharmaceutical Industries Ltd. Recent Development

Table 83. Novo Nordisk A/S Company Details

Table 84. Novo Nordisk A/S Business Overview

Table 85. Novo Nordisk A/S Oral Obesity Therapies Product

Table 86. Novo Nordisk A/S Revenue in Oral Obesity Therapies Business (US$ Million), 2021–2026

Table 87. Novo Nordisk A/S Recent Development

Table 88. Pfizer Inc. Company Details

Table 89. Pfizer Inc. Business Overview

Table 90. Pfizer Inc. Oral Obesity Therapies Product

Table 91. Pfizer Inc. Revenue in Oral Obesity Therapies Business (US$ Million), 2021–2026

Table 92. Pfizer Inc. Recent Development

Table 93. Arena Pharmaceuticals, Inc. Company Details

Table 94. Arena Pharmaceuticals, Inc. Business Overview

Table 95. Arena Pharmaceuticals, Inc. Oral Obesity Therapies Product

Table 96. Arena Pharmaceuticals, Inc. Revenue in Oral Obesity Therapies Business (US$ Million), 2021–2026

Table 97. Arena Pharmaceuticals, Inc. Recent Development

Table 98. Rhythm Pharmaceuticals, Inc. Company Details

Table 99. Rhythm Pharmaceuticals, Inc. Business Overview

Table 100. Rhythm Pharmaceuticals, Inc. Oral Obesity Therapies Product

Table 101. Rhythm Pharmaceuticals, Inc. Revenue in Oral Obesity Therapies Business (US$ Million), 2021–2026

Table 102. Rhythm Pharmaceuticals, Inc. Recent Development

Table 103. Gelesis Company Details

Table 104. Gelesis Business Overview

Table 105. Gelesis Oral Obesity Therapies Product

Table 106. Gelesis Revenue in Oral Obesity Therapies Business (US$ Million), 2021–2026

Table 107. Gelesis Recent Development

Table 108. Research Programs/Design for This Report

Table 109. Key Data Information from Secondary Sources

Table 110. Key Data Information from Primary Sources

Table 111. Authors List of This Report

List of Figures

Figure 1. Oral Obesity Therapies Picture

Figure 2. Global Oral Obesity Therapies Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Oral Obesity Therapies Market Share by Type: 2025 vs 2032

Figure 4. Lipase Inhibitors Features

Figure 5. Sympathomimetic Appetite Suppressants Features

Figure 6. Oral GLP-1 Agonists Features

Figure 7. Other Features

Figure 8. Global Oral Obesity Therapies Market Size Comparison by Drug Type (US$ Million), 2021–2032

Figure 9. Small Molecules Features

Figure 10. Peptide Oral Features

Figure 11. Combination Drugs Features

Figure 12. Other Features

Figure 13. Global Oral Obesity Therapies Market Size Comparison by Patient Indication (US$ Million), 2021–2032

Figure 14. BMI ≥30 Primary Obesity Features

Figure 15. Overweight + Metabolic Comorbidities Features

Figure 16. Short-term Weight Reduction Features

Figure 17. Weight Maintenance Features

Figure 18. Global Oral Obesity Therapies Market Size by Application (US$ Million), 2021–2032

Figure 19. Global Oral Obesity Therapies Market Share by Application: 2025 vs 2032

Figure 20. Hospitals Case Studies

Figure 21. Retail Pharmacies Case Studies

Figure 22. Other Case Studies

Figure 23. Oral Obesity Therapies Report Years Considered

Figure 24. Global Oral Obesity Therapies Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 25. Global Oral Obesity Therapies Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 26. Global Oral Obesity Therapies Market Share by Region: 2025 vs 2032

Figure 27. Global Oral Obesity Therapies Market Share by Players in 2025

Figure 28. Global Oral Obesity Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 29. The Top 10 and 5 Players Market Share by Oral Obesity Therapies Revenue in 2025

Figure 30. North America Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. North America Oral Obesity Therapies Market Share by Country (2021–2032)

Figure 32. United States Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Canada Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Europe Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Europe Oral Obesity Therapies Market Share by Country (2021–2032)

Figure 36. Germany Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. France Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. U.K. Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Italy Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Russia Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Ireland Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Asia-Pacific Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Asia-Pacific Oral Obesity Therapies Market Share by Region (2021–2032)

Figure 44. China Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Japan Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. South Korea Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Southeast Asia Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. India Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Australia & New Zealand Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. Latin America Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Latin America Oral Obesity Therapies Market Share by Country (2021–2032)

Figure 52. Mexico Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 53. Brazil Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 54. Middle East & Africa Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 55. Middle East & Africa Oral Obesity Therapies Market Share by Country (2021–2032)

Figure 56. Israel Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 57. Saudi Arabia Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 58. UAE Oral Obesity Therapies Market Size YoY Growth (US$ Million), 2021–2032

Figure 59. Currax Pharmaceuticals, LLC Revenue Growth Rate in Oral Obesity Therapies Business (2021–2026)

Figure 60. Vivus, Inc. Revenue Growth Rate in Oral Obesity Therapies Business (2021–2026)

Figure 61. Roche Holding AG Revenue Growth Rate in Oral Obesity Therapies Business (2021–2026)

Figure 62. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Oral Obesity Therapies Business (2021–2026)

Figure 63. Sun Pharmaceutical Industries Ltd. Revenue Growth Rate in Oral Obesity Therapies Business (2021–2026)

Figure 64. Novo Nordisk A/S Revenue Growth Rate in Oral Obesity Therapies Business (2021–2026)

Figure 65. Pfizer Inc. Revenue Growth Rate in Oral Obesity Therapies Business (2021–2026)

Figure 66. Arena Pharmaceuticals, Inc. Revenue Growth Rate in Oral Obesity Therapies Business (2021–2026)

Figure 67. Rhythm Pharmaceuticals, Inc. Revenue Growth Rate in Oral Obesity Therapies Business (2021–2026)

Figure 68. Gelesis Revenue Growth Rate in Oral Obesity Therapies Business (2021–2026)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions